Background Relapse of small cell lung
Small cell lung cancer has an aggressive course and is usually widespread at presentation. Surgery has been advocated in truly limited disease, but this is rare.' The best therapeutic approach for the time being is chemotherapy. Several combination regimens administered over three to six months have improved median survival and there is at present no clear advantage for any particular regimen.2 Unfortunately, the disease usually relapses a few months after discontinuation of chemotherapy and the benefit of further treatment at this stage is less clear.
We Cx-polychemotherapy course with carboplatin, etoposide, and epirubicin; LI-local irradiation; CI-cranial irradiation.
Collard, Weynants, Francis, Rodenstein Treatment policy on relapse is controversial and many patients and physicians are reluctant to consider further chemotherapy.7 A recent editorial states that further chemotherapy after the induction phase is not useful and that survival is not improved.8 It is also widely believed that if further treatment is prescribed it should be based on drugs other than those used in the induction regimen.
When a patient has shown a complete response to induction treatment we have elected to use the same treatment for relapse. As these cases show, we have had encouraging results with minimal toxicity. So far we have observed a response to relapse treatment with carboplatin-etoposide-epirubicin in every patient meeting the conditions of a complete initial response and a prolonged first remission of at least 12 months after finishing induction treatment.
A further course of induction treatment has proved effective in other malignancies, such as breast cancer,9 10 ovarian cancer," multiple myeloma,"2 and Hodgkin's disease.'3 A few studies have indicated that further treatment with the initial chemotherapeutic regimen may be effective in patients with small cell lung cancer who relapse after a short induction course.""'6 The response to initial treatment, the length of remission, and performance status may have prognostic significance in this context. As in our cases, the complete response rate and duration of remission tend to be shorter after reinduction chemotherapy than after the initial treatment. The carboplatin-etoposide-epirubicin chemotherapy appeared to be active against disease at other sites, including cerebral metastases (table and   figs In contrast to the results in these patients, the response rate with salvage treatment (whether carboplatin-etoposide-epirubicin; an alternative chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and methotrexate; or radiotherapy) has been very poor in our hands for patients with an initial partial response or short term remission after complete response to induction treatment with carboplatin-etoposideepirubicin.
Although a definite policy on relapse treatment will be arrived at only after large scale randomised trials, our preliminary experience suggests that using the same carboplatinetoposide-epirubicin chemotherapy regimen for relapse in small cell lung cancer may be an effective (albeit palliative) treatment provided that the initial response was complete and the first remission was prolonged.
Although the response to chemotherapy at relapse is disappointing for most patients with small cell lung cancer, identifying patients likely to derive benefit from repeated chemotherapy is important, in terms both of survival and of quality of life. The subgroup we have defined represents about 10% of patients with small cell lung cancer. If our findings are confirmed in a larger number of patients, with similar characteristics, the current policy of no further treatment after relapse will need to be revised so that patients will not be denied a potentially useful and well tolerated retreatment.
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